eXoZymes Partners With B2i Digital to Showcase Cell-Free Biomanufacturing Platform

B2i Digital has announced that eXoZymes Inc. has been named a B2i Digital Featured Company, bringing attention to the company's innovative approach to biomanufacturing. eXoZymes develops a cell-free, AI-guided enzyme platform that enables partners to design and run enzyme pathways for producing target chemicals. This technology represents a significant advancement in industrial biotechnology by providing a scalable, lower-impact alternative to petrochemical processes, natural extraction, and conventional synthetic biology methods.

David Shapiro, CEO of B2i Digital, expressed enthusiasm about introducing eXoZymes to the investment community. The company's cell-free enzyme technology specifically addresses the scale-up bottleneck that has challenged first-generation synthetic biology approaches. This positioning makes eXoZymes particularly relevant for investors focused on sustainable industrial biotechnology solutions that can replace selected petrochemical processes with more environmentally friendly biosolutions. Additional information about B2i Digital's services can be found at https://b2idigital.com.

Michael Heltzen, CEO of eXoZymes, emphasized the significance of the partnership in communicating the commercial potential of their exozymes platform. The company believes that cell-free biomanufacturing represents the next generation of industrial biotechnology. This collaboration with B2i Digital will enhance visibility among investors who recognize the value of scalable enzyme-based approaches as alternatives to traditional manufacturing methods. The company's website at https://exozymes.com provides further details about their technology platform.

The eXoZymes platform represents a historic breakthrough in biomanufacturing by liberating enzyme-driven chemical reactions from cellular constraints. The company's advanced enzymes, known as exozymes, are enhanced through artificial intelligence and bioengineering to function effectively in bioreactors without requiring living cells. This innovative approach enables the transformation of biomass into essential natural products, medicines, chemicals, and biofuels. The technology offers partners a commercially viable pathway to scalable and sustainable production of small molecules at industrial scale, addressing key limitations of existing biomanufacturing methods.

eXoZymes initially targets low volume, high value natural products with potential pharmaceutical applications, demonstrating the platform's versatility across multiple industries. The cell-free nature of the technology eliminates many of the challenges associated with maintaining living cells in industrial processes, including contamination risks and metabolic burdens. This partnership with B2i Digital comes at a crucial time as industries worldwide seek more sustainable manufacturing solutions that reduce environmental impact while maintaining commercial viability at scale.